|
|
| Polyclonal Antibody to CUEDC2 |
| Catalog No |
: |
IMG-6279A |
| Formulation |
: |
100 ug in 200 ul PBS containing 0.05% BSA and 0.05% sodium azide. Sodium azide is highly toxic. |
| Isotype |
: |
Rabbit IgG |
| Purification |
: |
Protein A chromatography |
| Species React |
: |
Chimpanzee, Cow, Dog, Horse, Human, Mouse, Pig, Rhesus Monkey |
| Predicted React |
: |
Opossum, Rat |
| Host |
: |
Rabbit |
|
| Application
Western blot analysis: 0.5-1.0 ug/ml
Storage
Store at 4°C, stable for 6 months. For long-term storage, aliquot and store at -20°C.
Recommended Positive Control : MCF7 and NIH 3T3 cell lysates |
|
Background
CUEDC2 is a 287 amino acid protein belonging to the CUEDC2 family with a CUE domain. CUEDC2 is known to interact with PGR and ESR1 with the help of its CUE domain. The exact function of CUEDC2 is yet unknown, but reports suggest that it interacts with PR and promotes progesterone-induced PR degradation by the ubiquitin-proteasome pathway. CUEDC2 participates in ubiquitination and subsequent proteasomal degradation of PGR and ESR1 and thus control their protein levels and plays an important role in breast cancer proliferation. Studies on CUEDC2 suggest that it acts as an adaptor protein that interacts with IKK and regulates IKK dephosphorylation by recruiting PP1. |
Antigen
A portion of amino acid 250-300 of human CUEDC2 was used as the immunogen. |
Application Notes
The amino acid sequence used as immunogen is 100% homologous in human, pig, horse, mouse, rhesus monkey, cow, dog and chimpanzee, 93% homologous in rat and 75% homologous in opossum, platypus and mouse. |
Genebank Info (Protein)
NP_076945 |
|
 |
Western blot analysis of CUEDC2 in MCF7 cell lysate in the 1) absence and 2) presence of immunizing peptide, 3) NIH 3T3 cell lysate, and 4) human spleen cell lysate using IMG-6279A at 0.5 ug/ml. |
|
|
|
|
|
|
Reference
1. Strausberg, RL. et al. Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
2. Zhang, PJ. et al. EMBO. J. 26:1831-1842 (2007).
3. Hui-Yan Li, et al. Nature Immunology. 9:533-541 (2008).
|
